Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (21-30 of 218) with videos related to

Pageof 22
Sort By:
Cancers|June 2, 2021
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for TherapyMaurice Michel, Leonard Kaps, Annett Maderer, et al.
Best Practice & Research. Clinical Gastroenterology|December 12, 2007
The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancerMarkus Moehler, P R Galle, I Gockel, et al.
International Journal of Cancer|November 16, 2012
Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1Maike Sieben, Petra Schäfer, Christiane Dinsart, et al.
Journal of Patient-Reported Outcomes|March 28, 2026
PROMs: Patient related or patient centred? A bridge between Patient-Reported Outcome Measures (PROMs) and clinical ethics in the context of a cohort of gynaeco-oncological patients analysed by qualitative semi- structured interviewsSusanne Theis, Hamideh Fruehwein, Annette Hasenburg, et al.
Oncotargets and Therapy|August 30, 2013
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cellsBernd Heinrich, Katrin Goepfert, Maike Delic, et al.
Digestive Diseases (Basel, Switzerland)|April 7, 2005
(Neo)adjuvant strategies of advanced gastric carcinoma: time for a change?Markus Moehler, Carl C Schimanski, Ines Gockel, et al.
Deutsches Arzteblatt International|October 14, 2025
Gastric Carcinoma: Diagnosis, Staging, and TreatmentYvonne Huber, Susanne Unverzagt, Petra Lynen Jansen, et al.
Frontiers in Oncology|July 25, 2025
Escalation, maintenance and abstention in oncology a new study design to identify how individual values of patients impact on the assessment of risks and benefits of novel therapeutic concepts in cases of gynaecological tumors and colorectal cancer: a study protocolSusanne Theis, Jülide Senyigit, Britta Büchler, et al.
Oncology Letters|July 12, 2012
Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuouslyThomas C Wehler, Yang Cao, Peter R Galle, et al.
BMC Cancer|February 17, 2012
Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control studyGeorge Sgourakis, Ines Gockel, Constantine Karaliotas, et al.
Pageof 22

Showing results (21-30 of 218) with videos related to

Sort By:
Pageof 22
Cancers|June 2, 2021
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for TherapyMaurice Michel, Leonard Kaps, Annett Maderer, et al.
Best Practice & Research. Clinical Gastroenterology|December 12, 2007
The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancerMarkus Moehler, P R Galle, I Gockel, et al.
International Journal of Cancer|November 16, 2012
Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1Maike Sieben, Petra Schäfer, Christiane Dinsart, et al.
Journal of Patient-Reported Outcomes|March 28, 2026
PROMs: Patient related or patient centred? A bridge between Patient-Reported Outcome Measures (PROMs) and clinical ethics in the context of a cohort of gynaeco-oncological patients analysed by qualitative semi- structured interviewsSusanne Theis, Hamideh Fruehwein, Annette Hasenburg, et al.
Oncotargets and Therapy|August 30, 2013
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cellsBernd Heinrich, Katrin Goepfert, Maike Delic, et al.
Digestive Diseases (Basel, Switzerland)|April 7, 2005
(Neo)adjuvant strategies of advanced gastric carcinoma: time for a change?Markus Moehler, Carl C Schimanski, Ines Gockel, et al.
Deutsches Arzteblatt International|October 14, 2025
Gastric Carcinoma: Diagnosis, Staging, and TreatmentYvonne Huber, Susanne Unverzagt, Petra Lynen Jansen, et al.
Frontiers in Oncology|July 25, 2025
Escalation, maintenance and abstention in oncology a new study design to identify how individual values of patients impact on the assessment of risks and benefits of novel therapeutic concepts in cases of gynaecological tumors and colorectal cancer: a study protocolSusanne Theis, Jülide Senyigit, Britta Büchler, et al.
Oncology Letters|July 12, 2012
Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuouslyThomas C Wehler, Yang Cao, Peter R Galle, et al.
BMC Cancer|February 17, 2012
Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control studyGeorge Sgourakis, Ines Gockel, Constantine Karaliotas, et al.
Pageof 22